Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Robert Baker

Pediatric Anesthesiology Springdale, AR Medical Doctor

NPI 1013069699 CMS profile 591159

2601 Gene George Blvd, Springdale, AR 72762

Open in the dashboard

General payments

$1,715

79 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Robert Baker of Springdale, AR is reported in the CMS Open Payments database as having received $1,715 across 79 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Pediatric Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $176 13
2022 General $99 5
2021 General $530 12
2020 General $200 11
2019 General $711 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Baker
  • Pediatric Anesthesiology median
  • Middle half of Pediatric Anesthesiology
  • National median

In program year 2025, general payments to Robert Baker were reported at $0. Among 387 Pediatric Anesthesiology profiles paid that year, the median was $41 and the middle half received between $21 and $103.

Show as a table
Year Robert Baker Pediatric Anesthesiology median Middle half National median
2019 $711 $87 $23–$151 $163
2020 $200 $36 $16–$140 $114
2021 $530 $49 $19–$142 $132
2022 $99 $36 $19–$132 $149
2023 $176 $39 $22–$123 $160
2024 $0 $41 $23–$129 $164
2025 $0 $41 $21–$103 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Medtronic, Inc. $666 23 payments
  2. Boston Scientific Corporation $317 11 payments
  3. Abbott Laboratories $188 8 payments
  4. Biodelivery Sciences International, Inc. $157 13 payments
  5. Lilly USA, LLC $126 7 payments
  6. Daiichi Sankyo Inc. $106 8 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $44 3 payments
  8. Pfizer Inc. $41 2 payments
  9. Flexion Therapeutics, Inc. $22 1 payment
  10. Medtronic USA, Inc. $17 1 payment
  11. Other $31 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,545 77 payments
  2. Travel and Lodging $170 2 payments
Products named General payments · program years 2019–2023
  1. INTELLIS $454 7 payments
  2. GENERAL PAIN MANAGEMENT $253 7 payments
  3. BUNAVAIL 2.1 mg 30-count box $127 11 payments
  4. BUNAVAIL 2.1 mg single pouch $127 11 payments
  5. BUNAVAIL 4.2 mg 30-count box $127 11 payments
  6. BUNAVAIL 4.2 mg single pouch $127 11 payments
  7. BUNAVAIL 6.3 mg 30-count box $127 11 payments
  8. INTELLIS ADAPTIVESTIM $125 8 payments
  9. EMGALITY $108 6 payments
  10. Morphabond ER $97 7 payments
  11. Other $568 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,318

Median for Pain Management: 951

Drug cost

$73,127

Median for Pain Management: $26,034

Branded share of claims

46.4%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 33 $28,073
Buprenorphine Generic 48 $11,990
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 323 $9,602
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 191 $6,812
Oxycodone Hcl Generic 212 $3,741
Naloxone Hcl Generic 49 $3,065
Morphine Sulfate Er Morphine Sulfate Brand 65 $2,288
Pregabalin Generic 63 $1,555
Buprenorphine Hcl Generic 16 $1,486
Gabapentin Generic 85 $1,082

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$113,908

Medicare's payments for the services billed

Medicare patients

241

Average age 70

Services billed

1,169

135 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 45%
Ischemic heart disease 44%
Diabetes 33%
Chronic kidney disease 31%
COPD 27%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Anesthesiology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record